Literature DB >> 9258552

Prevalence and antifungal susceptibility of vaginal yeasts in outpatients attending a gynecological center in Ancona, Italy.

D Arzeni1, M Del Poeta, O Simonetti, A M Offidani, L Lamura, M Balducci, N Cester, A Giacometti, G Scalise.   

Abstract

Between February 1993 and May 1994 we studied the prevalence of fungal vulvovaginitis among women attending the Obstetric and Gynecology Clinic of the University of Ancona. Out of the 222 patients, 18 (8.2%) women had symptomatic vaginitis and 24 (10.8%) were carriers. Candida albicans was the species most frequently isolated (44.2%), followed by Torulopsis glabrata (28%) and Saccharomyces cerevisiae (16.2%), from symptomatic and carrier patients. The activity of acid proteinase was determined for C. albicans isolated from both symptomatic and carrier patients. All 13 carriers showed low activity for aspartyl proteinase (score 1+), while 5 of 6 symptomatic patients showed higher activity (score 2+), with a significant difference (p = 0.026). In general, isolates of T. glabrata and S. cerevisiae were less susceptible in vitro to fluconazole than isolates of C. albicans. We did not find any differences in fluconazole MIC results among the C. albicans strains isolated from symptomatic and carrier patients. On the other hand, the fluconazole MICs of T. glabrata and S. cerevisiae isolates showed statistically significant differences between symptomatic and carrier patients (p = 0.009 and p = 0.000, respectively). The differences in proteinase secretion between the isolates from symptomatic and carrier patients suggest a correlation between proteinase production and vaginal candidiasis caused by C. albicans. Torulopsis glabrata, however, was found to be the most common causative agent of vaginitis (7 out 19 episodes), followed by C. albicans (6 out of 19 episodes). Due to the varying patterns of antifungal susceptibility, mainly to fluconazole for the yeast isolates considered in this study, an in vitro susceptibility testing program might be useful for monitoring the outcome of this infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9258552     DOI: 10.1023/a:1007366722235

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  11 in total

Review 1.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

2.  Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.

Authors:  J R Wingard; W G Merz; M G Rinaldi; T R Johnson; J E Karp; R Saral
Journal:  N Engl J Med       Date:  1991-10-31       Impact factor: 91.245

3.  Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients.

Authors:  F Barchiesi; V Morbiducci; F Ancarani; G Scalise
Journal:  Eur J Epidemiol       Date:  1993-07       Impact factor: 8.082

4.  Secretion of acid proteinases by different species of the genus Candida.

Authors:  R Rüchel; K Uhlemann; B Böning
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1983-11

Review 5.  Vaginal infections in adult women.

Authors:  J D Sobel
Journal:  Med Clin North Am       Date:  1990-11       Impact factor: 5.456

6.  Genetic evidence for role of extracellular proteinase in virulence of Candida albicans.

Authors:  K J Kwon-Chung; D Lehman; C Good; P T Magee
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

7.  The secretion of aspartyl proteinase, a virulence enzyme, by isolates of Candida albicans from the oral cavity of HIV-infected subjects.

Authors:  F De Bernardis; M Boccanera; L Rainaldi; C E Guerra; I Quinti; A Cassone
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

8.  Evidence for a correlation between proteinase secretion and vulvovaginal candidosis.

Authors:  A Cassone; F De Bernardis; F Mondello; T Ceddia; L Agatensi
Journal:  J Infect Dis       Date:  1987-11       Impact factor: 5.226

9.  Management of persistent vulvo vaginal candidosis due to azole-resistant Candida glabrata.

Authors:  D J White; E M Johnson; D W Warnock
Journal:  Genitourin Med       Date:  1993-04

10.  Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard.

Authors:  F Barchiesi; A L Colombo; D A McGough; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

View more
  5 in total

1.  Detection of FUR1 Gene in 5-Flucytosine Resistant Candida Isolates in Vaginal Candidiasis Patients.

Authors:  Sasikala Gopinathan; Anand B Janagond; David Agatha; Thenmozhivalli P R
Journal:  J Clin Diagn Res       Date:  2013-11-10

2.  Prevalence of vulvovaginal candidiasis, trichomoniasis and bacterial vaginosis among pregnant women receiving antenatal care in Southwestern Nigeria.

Authors:  Olugbenga Adekunle Olowe; Olufunmilola Bamidele Makanjuola; Rita Olowe; Daniel A Adekanle
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2014-12-16

3.  Correlation between azole susceptibilities, genotypes, and ERG11 mutations in Candida albicans isolates associated with vulvovaginal candidiasis in China.

Authors:  Shu-Hua Ge; Zhe Wan; Juan Li; Jianping Xu; Ruo-Yu Li; Feng-Yan Bai
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

4.  Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases.

Authors:  Sandra S Richter; Rudolph P Galask; Shawn A Messer; Richard J Hollis; Daniel J Diekema; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

5.  Vulvovaginal candidiasis in Mato Grosso, Brazil: pregnancy status, causative species and drugs tests.

Authors:  Luciana Basili Dias; Márcia de Souza Carvalho Melhem; Maria Walderez Szeszs; José Meirelles Filho; Rosane Christine Hahn
Journal:  Braz J Microbiol       Date:  2011-12-01       Impact factor: 2.476

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.